Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 7/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicoboxil SCHEMBL29475326 | 1.00 | L3MBTL1 (0.84) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL25951682 | 0.95 | LMNA (0.85) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL551716 | 0.91 | L3MBTL1 (1.00) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| Nicoboxil SCHEMBL14917483 | 0.91 | TDP1 (0.70) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL5559952 | 0.90 | L3MBTL1 (0.97) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL551811 | 0.87 | LMNA (0.97) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL25329932 | 0.86 | L3MBTL1 (0.62) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| Sulfuric Acid SCHEMBL11419955 | 0.86 | L3MBTL1 (0.89) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL4275232 | 0.86 | LMNA (1.00) | L3MBTL1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL285214 | 0.86 | LMNA (1.00) | L3MBTL1LMNAKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1044 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| US-20080160070-A1 | TRANSDERMAL VITAMIN B12 DELIVERY PATCH | NEXAGEN USA LLC (US) | 2008-07-03 | — | — | US | claimed |
| EP-1938789-A1 | Improvement of the skin friendliness of hyperemizing agents | Henkel AG & Co. KGaA (DE) | 2008-07-02 | — | — | EP | claimed |
| EP-1890769-A1 | HAIR TONIC | INDENA S.p.A. (IT) | 2008-02-27 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006114188-A1 | HAIR TONIC | INDENA S.P.A. (IT) | 2006-11-02 | — | — | WO | claimed |
| US-20060093656-A1 | Warming patch | HISAMITU PHARMACEUTICAL CO., INC. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1568365-A1 | WARM POULTICE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2005-08-31 | — | — | EP | claimed |
| WO-2005051365-A1 | COMPOSITION AND DEVICE FOR FACILITATING VENIPUNCTURE | MEDIS S.R.L. (IT) | 2005-06-09 | — | — | WO | claimed |
| EP-0242827-B1 | SURFACE SHAPED THERAPEUTIC SYSTEM, METHOD FOR ITS MANUFACTURE, AND ITS APPLICATION | Lohmann GmbH & Co. KG (DE) | 1991-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | L3MBTL1 3949/4885LMNA 512/4885KMT2A 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.